Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307904 | 0.98 | NAAA (0.51) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL4307833 | 0.95 | NAAA (0.53) | NAAAEPHX1HTTALDH1A1 | |
| SCHEMBL4310562 | 0.94 | NAAA (0.54) | NAAAEPHX1HTTALDH1A1 | |
| SCHEMBL450932 | 0.90 | NAAA (0.45) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL8630969 | 0.88 | NAAA (0.46) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL451498 | 0.88 | NAAA (0.46) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL8691006 | 0.86 | NAAA (0.41) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL450993 | 0.82 | EPHX1 (0.46) | NAAAEPHX1HTTALDH1A1CYP2C19 | |
| SCHEMBL8691321 | 0.82 | NAAA (0.36) | NAAAEPHX1ALDH1A1 | |
| SCHEMBL8579933 | 0.81 | EPHX1 (0.49) | NAAAEPHX1HTTALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| US-6844173-B2 | Strain of Streptomyces griseus | SANKYO COMPANY, LIMITED (JP) | 2005-01-18 | — | — | US | disclosed |
| EP-1319666-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| EP-1319406-A1 | Novel antibacterial compounds | Sankyo Company, Limited (JP) | 2003-06-18 | — | — | EP | disclosed |
| US-20030069204-A1 | Strain of streptomyces | SANKYO COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | NAAA 108/4885EPHX1 631/4885HTT 2210/4885 |
| US-20030069204-A1 | Strain of streptomyces | O60361, CYP8B1, MRPS34 | NAAA 220/4885EPHX1 769/4885HTT 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.